Products for Research Use Only
RegisterLogin

Lixumistat

CAT: 0804-HY-136093B-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-136093B-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus[1][5].
CAS Number
1422365-93-2
Product Name Alternative
IM156 (free base) ; HL156A (free base) ; HL271 (free base)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Mitochondrial Metabolism
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lixumistat.html
Concentration
10mM
Purity
99.33
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
N=C(N1CCCC1)NC(NC2=CC=C(OC(F)(F)F)C=C2)=N
Molecular Formula
C13H16F3N5O
Molecular Weight
315.29
Precautions
H302, H315, H319, H335
References & Citations
[1]Willette RN, et al. Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis. J Pharmacol Exp Ther. 2021 Nov;379 (3) :290-300.|[2]Shim JS, et al. The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus. Kidney Int. 2023 Feb;103 (2) :343-356.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

CatalogName
C14354-01Lixumistat (IM156)

Popular Products